These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 24646011

  • 1. Current approach to iron chelation in children.
    Aydinok Y, Kattamis A, Viprakasit V.
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [Abstract] [Full Text] [Related]

  • 2. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M, Borgna-Pignatti C.
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [Abstract] [Full Text] [Related]

  • 3. Post-transfusional iron overload in the haemoglobinopathies.
    Thuret I.
    C R Biol; 2013 Mar; 336(3):164-72. PubMed ID: 23643400
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R.
    Ann N Y Acad Sci; 2005 May; 1054():183-5. PubMed ID: 16339664
    [Abstract] [Full Text] [Related]

  • 6. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE, SWiTCH Study Investigators.
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 8. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A.
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [Abstract] [Full Text] [Related]

  • 9. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD.
    Blood Cells Mol Dis; 2014 Jan 01; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract] [Full Text] [Related]

  • 11. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 01; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 12. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Aug 01; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 13. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 01; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 14. Beta-thalassemia.
    Rund D, Rachmilewitz E.
    N Engl J Med; 2005 Sep 15; 353(11):1135-46. PubMed ID: 16162884
    [No Abstract] [Full Text] [Related]

  • 15. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 15; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 16. Evaluation and treatment of transfusional iron overload in children.
    Ware HM, Kwiatkowski JL.
    Pediatr Clin North Am; 2013 Dec 15; 60(6):1393-406. PubMed ID: 24237978
    [Abstract] [Full Text] [Related]

  • 17. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K, Tzoumari I, Pappa C.
    Blood Cells Mol Dis; 2011 Jun 15; 47(1):33-40. PubMed ID: 21531154
    [Abstract] [Full Text] [Related]

  • 18. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
    Koh KN, Park M, Kim BE, Im HJ, Seo JJ.
    J Pediatr Hematol Oncol; 2010 Nov 15; 32(8):611-4. PubMed ID: 20881872
    [Abstract] [Full Text] [Related]

  • 19. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
    Ho PJ, Tay L, Lindeman R, Catley L, Bowden DK.
    Intern Med J; 2011 Jul 15; 41(7):516-24. PubMed ID: 21615659
    [Abstract] [Full Text] [Related]

  • 20. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V, Neokleous N, Agapidou A, Economou M, Vetsiou E, Teli A, Perifanis V.
    Ann Hematol; 2013 Jan 15; 92(2):263-5. PubMed ID: 22933235
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.